Cargando…
Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues
Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in development as a nebulized inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) patients. This study evaluated the pharmacology of revefenacin at h...
Autores principales: | Hegde, Sharath S., Pulido‐Rios, M. Teresa, Luttmann, Mark A., Foley, James J., Hunsberger, Gerald E., Steinfeld, Tod, Lee, TaeWeon, Ji, Yuhua, Mammen, Mathai M., Jasper, Jeffrey R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927803/ https://www.ncbi.nlm.nih.gov/pubmed/29736245 http://dx.doi.org/10.1002/prp2.400 |
Ejemplares similares
-
Revefenacin, a once-daily, long-acting muscarinic antagonist, for
nebulized maintenance therapy in patients with chronic obstructive pulmonary
disease
por: Hvisdas, Christopher
Publicado: (2021) -
Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation
por: Witte, Lambertus P. W., et al.
Publicado: (2011) -
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020) -
Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019) -
Investigating the
Unbinding of Muscarinic Antagonists
from the Muscarinic 3 Receptor
por: Buigues, Pedro J., et al.
Publicado: (2023)